InSilico Medicine Cayman TopCo vs Akeso: why the prices moved differently

• ▲

  Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

  These are the largest new partnerships this period and directly boost demand for Insilico's platform.

• ▲

  First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

  Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

• ▲

  Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

  Index inclusion is a new capital-flow catalyst that can support the share price.

• ▲

  Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

  It explains the broader industry force behind Insilico's deal momentum and investor interest.

Based on 6 stories →

• ▲

  U.S. rules may let Chinese drug licensing deals go ahead Washington is drafting rules that would likely allow U.S. drugmakers to license medicines from Chinese biotechs, excluding weaponizable biotech. Akeso shares jumped 8% on the news. If it holds, Akeso keeps access to the big, high-priced U.S. market — the main reason its pipeline is worth so much.

  This is the single biggest new force on Akeso's price: it protects the overseas licensing route that underpins its valuation.

• ▲

  AstraZeneca puts $2B into Summit and will test ivonescimab combos AstraZeneca will invest $2 billion in Summit, Akeso's overseas partner, and lead trials combining Akeso's ivonescimab with its own cancer drugs in gut tumors. A global pharma giant funding and running studies raises confidence in ivonescimab's overseas path and cuts Akeso's own development risk.

  A major partner's money and trial backing directly strengthens the case for Akeso's flagship drug abroad.

• ▲

  Cadonilimab moves into global and new-indication trials Akeso started a global Phase III gastric-cancer trial for cadonilimab and dosed the first patient in a Phase III colon-cancer study, where earlier data showed an 84.6% complete response. Each new indication widens the drug's future sales base, though revenue is still years away.

  These trials expand the long-term sales potential of Akeso's second big drug beyond its current approved uses.

• ▲

  Ivonescimab data and new combo trial keep pipeline momentum Positive survival data for ivonescimab in biliary tract cancer was picked for ESMO's top session, with about 30 bispecific studies to be presented. A Phase II breast-cancer trial combining a new ADC with ivonescimab also began. More proof points support the drug's breadth, but they are early-stage.

  It shows the flagship drug and pipeline are still producing data that can support future approvals and sales.

Based on 6 stories →

• ▲

  Ivonescimab beats Keytruda on overall survival Akeso's ivonescimab cut the risk of death by 27% versus Merck's Keytruda in a China Phase 3 lung-cancer trial, with patients living a median 30.8 months versus 22.6. This is the strongest proof yet that Akeso's flagship drug may be better than the world's best-selling cancer drug, lifting its long-term sales outlook.

  The survival win is the period's biggest value driver for 9926.HK.

• ▲

  Benefit strongest in high PD-L1 patients In patients whose tumors had high PD-L1 levels, ivonescimab cut death risk by 42%. In lower-PD-L1 patients the benefit was smaller and not statistically reliable. So the drug's edge is real but narrower than headlines suggest, which tempers how much extra sales investors should assume.

  It is the honest counterweight inside the same trial result.

• ▲

  Global confirmatory trial and FDA decision ahead Summit is recruiting 780 patients for HARMONi-7, a global trial testing ivonescimab against Keytruda, and the FDA is reviewing a separate application in previously treated EGFR-mutated lung cancer with a November 14 decision date. Success would open the much larger U.S. and European markets.

  It shows the path from China approval to global revenue.

• ▲

  Two new ADCs cleared for human testing China's drug regulator cleared Phase 1 trials for AK157D1, a B7-H3 ADC, and AK158D1, a bispecific EGFR/TROP2 ADC. These are Akeso's third and fourth ADCs to reach the clinic, showing a deep pipeline beyond ivonescimab, though any revenue is years away.

  Pipeline breadth supports the long-term growth story.

Based on 6 stories →

• ▲

  New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

  This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

• ▲

  Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

  It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

• ▲

  Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

  It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

• ▲

  Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

  It explains the market backdrop pushing the whole sector, including Akeso, higher this period.

Based on 6 stories →